|
English
|
正體中文
|
简体中文
|
总笔数 :0
|
|
造访人次 :
53305508
在线人数 :
1061
教育部委托研究计画 计画执行:国立台湾大学图书馆
|
|
|
"shao y y"的相关文件
显示项目 86-95 / 396 (共40页)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每页显示[10|25|50]项目
| 臺大學術典藏 |
2022-01-24T06:05:34Z |
Early changes in dce-mri biomarkers may predict survival outcomes in patients with advanced hepatocellular carcinoma after sorafenib failure: Two prospective phase ii trials
|
Chen B.-B.; Lin Z.-Z.; Shao Y.-Y.; CHIUN HSU; Hsieh C.-H.; Cheng A.-L.; Liang P.-C.; Shih T.T.-F. |
| 臺大學術典藏 |
2022 |
ICOS-Positive Regulatory T Cells in Hepatocellular Carcinoma: The Perspective from Digital Pathology Analysis
|
Lu L.-C.; Deantonio C.; Palu C.C.; Lee Y.-H.; Mitchell L.S.; Cowan M.; Corser M.; Sherry L.; Cheng A.-L.; Quaratino S.; Shao Y.-Y.; Sainson R.C.A.; CHIH-HUNG HSU |
| 臺大學術典藏 |
2022 |
Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma
|
Shao Y.-Y.; Cheng A.-L.; CHIH-HUNG HSU; Hsu C.; Lin Z.-Z.; Lu L.-C.; Chen B.-B.; Liang P.-C.; Shih T.T.-F.; Liu T.-H.; Shen Y.-C. |
| 國立成功大學 |
2022 |
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment
|
Chen, Chen C.-T.;Feng, Y.-H.;Yen, C.-J.;Chen, S.-C.;Lin, Y.-T.;Lu, Lu L.-C.;Hsu, C.-H.;Cheng, A.-L.;Shao, Y.-Y. |
| 國立成功大學 |
2022 |
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
|
Shao, Y.-Y.;Feng, Y.-H.;Yen, C.-J.;Yang, T.-S.;Shen, Y.-C.;Chao, Y.;Chen, J.-S.;Su, C.-Y.;Chen, W.-J.;Hsiang, Hsiang H.-L.;Hsu, C.-H. |
| 國立成功大學 |
2022 |
Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma
|
Shao, Y.-Y.;Chen, P.-S.;Lin, Lin L.-I.;Lee, B.-S.;Ling, A.;Cheng, A.-L.;Hsu, C.;Ou, D.-L. |
| 臺大學術典藏 |
2021-09-01T01:54:22Z |
Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment
|
Shao Y.-Y.; Lin Z.-Z.; Liang P.-C.; Tien Y.-W.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions
|
Shao Y.-Y.; Hu F.-C.; Liang J.-T.; Chiu W.-T.; ANN-LII CHENG; Yang C.-H. |
| 臺大學術典藏 |
2021-09-01T01:54:17Z |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma
|
Hsu C.-H.; Shen Y.-C.; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:54:16Z |
Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin
|
Shao Y.-Y.; Kuo K.-T.; Hu F.-C.; Lu Y.-S.; Huang C.-S.; Liau J.-Y.; Lee W.-C.; Hsu C.; Kuo W.-H.; Chang K.-J.; Lin C.-H.; ANN-LII CHENG |
显示项目 86-95 / 396 (共40页)
<< < 4 5 6 7 8 9 10 11 12 13 > >>
每页显示[10|25|50]项目
|
